Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-777991 in adults with non-segmental vitiligo
2025-524865-25-00Phase 2Authorised
- Sponsor
- Idorsia
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in Vitiligo comparing ACT-777991 with Matching placebo (2 arms). Primary endpoints: Percentage change from baseline in F-VASI based on blinded independent central reading at Week 24, Percentage change from baseline in F-VASI based on investigator assessment at Week 24 and 4 more. Planned start Oct 2026; status: authorised.
02
Drugs
ACT-777991
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2025-524865-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524865-25-00.